Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tarsus Pharmaceuticals Inc (NQ: TARS ) 33.49 +0.98 (+3.01%) Streaming Delayed Price Updated: 10:50 AM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Tarsus Pharmaceuticals Inc < Previous 1 2 3 4 Next > Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 September 25, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference August 28, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 August 08, 2024 TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements August 08, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Analyst Ratings For Tarsus Pharmaceuticals May 09, 2024 Via Benzinga Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) is a Stock Spotlight on 4/15 April 15, 2024 Via Investor Brand Network Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 July 29, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session July 26, 2024 Via Benzinga A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts February 29, 2024 Via Benzinga Earnings Scheduled For February 27, 2024 February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. Via Benzinga Tarsus Pharmaceuticals's Earnings: A Preview February 26, 2024 Via Benzinga Tarsus to Participate in Upcoming Investor Conferences May 29, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Pre-Market Session May 13, 2024 Via Benzinga Simple Ways To Stay With Trends: The Week In Charts May 12, 2024 Has the market made its all-time highs? In this video I cover the stock and crypto markets. Via Talk Markets Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference May 09, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Pharmaceuticals - Mixed Projections February 02, 2024 Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Via Talk Markets Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 May 09, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session May 09, 2024 Via Benzinga TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 May 08, 2024 TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements May 08, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 May 01, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon April 23, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Participate at Upcoming Investor Conferences March 05, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis March 05, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Announces Pricing of $100.0 Million Public Offering March 01, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Announces Proposed $100.0 Million Public Offering February 29, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday February 28, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements February 27, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease February 22, 2024 TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 February 20, 2024 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
